On January 31, 2022, Chordate announced that the Company has received preliminary approval from Nasdaq Stockholm AB ("Nasdaq") regarding the List change. The first day for trading on the Nasdaq First North Growth Market is tentatively February 15th, 2022, subject to Chordate receiving final approval from Nasdaq, with the last day for trading on the Nordic SME being February 14th, 2022. Provided that Chordate receives final approval from Nasdaq, the company's shares will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

The Company description is not deemed to contain any previously unpublished information that could have a material effect on the price of the Company's share.

Advisor
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.

Information:
This disclosure was submitted for publication, through the contact person below, on February 10th, 2022, at 16:00 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

Vastra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se, is Chordate's Certified Adviser.

The following documents can be retrieved from beQuoted
Chordate-Medical-publishes-company-description-in-connection.pdf

Chordate-Medical-publishes-company-description-in-connection.pdf

The main purpose of the patient study, which began in 2018, was to enable a CE marking of the company's preventive treatment of chronic migraine. As Chordate received the CE marking on interim data in May 2021, the purpose is fulfilled, however, a positive result from the patient study is still extremely important for continued marketing activities. The goal is to get a scientific article published. The article is expected to be completed and submitted for scientific review during the third quarter of 2022.

The international patient study on the patented treatment method K.O.S for chronic migraine began in 2018. The study, which is being carried out at nine clinics in Germany and Finland, was suspended due to the covid-19 pandemic in 2020 but has been resumed in stages from the beginning of 2021, completely due to the development of the pandemic.

Information:
This disclosure was submitted for publication, through the contact person below, on February 2nd , 2022, at 12:50 pm CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-updates-on-patient-study-last-patient-to-start-trea.pdf

Chordate-updates-on-patient-study-last-patient-to-start-trea.pdf

As previously communicated, The Board believes that a change of trading venue for the company's shares to Nasdaq First North Growth Market will increase the knowledge of the company both in Sweden and internationally, making it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers. Overall, a change of trading venue is considered to be positive for Chordate's development and completion of the stated exit strategy.

Provided that Chordate receives final approval from Nasdaq, the company's shares will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

Advisor
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.

Information:
This disclosure was submitted for publication, through the contact person below, on January 31st, 2022, at 15:30 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-Medical-has-received-preliminary-approval-from-Nasd.pdf

Chordate-Medical-has-received-preliminary-approval-from-Nasd.pdf

The study, an open comparative observational study, was conducted between December 2018 and July 2020 with a total of 80 patients aged 18-87 years evenly distributed between women and men. Patients were divided into two equal groups, one of which was treated with one (1) K.O.S. treatment, and the control group was treated with standard nasal spray (mometasone furoate, eg Nasonex®).

The study measured outcomes from a) rhinomanometry that measures airflow resistance, b) odor test for odor ability, c) mucus transport ability, d) two different estimation scales for quality of life related to breathability (SNOT-22 and I-NOSE).

The measurements were made partly before the first treatment, partly 45 days after K.O.S treatment – respectively start in the study for the control group.

The results of the study showed significant improvements in the K.O.S group, and also in comparison with the control group, between the start of the study and the last measurement. Several important measurement results and comparisons showed significant differences.

The study can be read in its entirety here: https://www.ajsccr.org/article-details.php?tit=AJSCCR-v4-1670

The article's conclusion reads:
K.O.S treatment is a safe and mini-invasive procedure for the treatment of NAR symptoms, well accepted from the patients and with a promising improvement of QoL, as assessed with the improvement of I-NOSE and SNOT-22 score after the K.O.S application on patients. The procedure can be administered on an outpatient basis without the need for general/local anesthesia or any premedication and it presents an efficacy almost comparable to that of conventional medical therapy.

"It is very gratifying that there are research results that have been initiated and funded completely without our participation or knowledge. In this case, it is particularly exciting to read about a study that includes patients who are far much older than 65 years and who report such positive improvements in quality of life. As far as we know, this is also the first time someone has studied the effects on the sense of smell – and with such positive results", says Anders Weilandt, CEO of Chordate.

Information:
This disclosure was submitted for publication, through the contact person below, on January 31st, 2022, at 08:45 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Independent-scientific-article-published-on-the-K-O-S-treatm.pdf

Independent-scientific-article-published-on-the-K-O-S-treatm.pdf

As previously communicated, The Board believes that a change of trading venue for the company's shares to Nasdaq First North Growth Market will increase the knowledge of the company both in Sweden and internationally, making it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers. Overall, a change of trading venue is considered to be positive for Chordate's development and completion of the stated exit strategy. Nasdaq First North Growth Market is Nasdaq's European growth market, with the same legal status as NGM Nordic SME.

Provided that Chordate receives final approval from Nasdaq, the company's share will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

Advisor
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.

Information:
This disclosure was submitted for publication, through the contact person below, on January 28th, 2022, at 15:20 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-Medical-receives-decision-to-delist-its-shares-from.pdf

Chordate-Medical-receives-decision-to-delist-its-shares-from.pdf

As Chordate announced in October 2021, the company has made a strategic decision to initiate a pre-study study to apply for marketing authorization for the K.O.S treatment for chronic migraine with the US Food and Drug Administration, FDA. The pre-study will begin immediately through the collaboration with RQM+ and can be expected to be completed within the first quarter of 2022, when a decision on the choice of strategy can be made.

Information:
This disclosure was submitted for publication, through the contact person below, on December 13th, 2021, at 15:15 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-has-chosen-RQM-to-prepare-a-marketing-authorization.pdf

Chordate-has-chosen-RQM-to-prepare-a-marketing-authorization.pdf

As the company announced in November 2020, private health insurance companies in Saudi Arabia approved the insurance code that can be used by private care providers in the country when treating with K.O.S for chronic rhinitis. Now, the first insurance-reimbursed K.O.S treatment has been completed.

"One of our strategic goals is to prove the market opportunity in well-selected markets to enable expansion and growth and to be able to attract buyers of the company. Saudi Arabia is one of the markets selected and the news that the first privately insured patient now has been treated with K.O.S is a major step towards that goal."

Information:
This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on December 8th, 2021, at 14:50 a.m. CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
The-first-insurance-reimbursed-K-O-S-treatment-carried-out-i.pdf

The-first-insurance-reimbursed-K-O-S-treatment-carried-out-i.pdf

Chordate and Nanos Medical started a joint venture in 2018 and then formed a jointly owned company in Shanghai with the intention of marketing the K.O.S technology in the Chinese market. Nanos Medical owns 2/3 of this company, Changyong Medical Technology Co., and is the party that finances marketing and sales, Chordate will for its 1/3 submit the Chinese patents when product registration is in place.

In August, Chordate received a prepaid order for two new-generation K.O.S. machines which has since been delivered to Changyong Medical Technology Co. Ltd. The K.O.S machines are used in the work to obtain a national market permit for Chordate's technology for rhinitis treatment. The registration work is ongoing.

"This means that we still have a capital-strong partner in China who believes in and invests in the K.O.S treatment for rhinitis. Nanos Medical is said to be the Number One actor on the Ear/Nose/Throat-market in China", says Anders Weilandt, CEO of Chordate Medical.

Information:
This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on December 6th, 2021, at 15:00 a.m. CET.

For more information, please contact:
Anders Weilandt
Managing Director
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-Medical-signs-new-joint-venture-agreement-with-Nano.pdf

Chordate-Medical-signs-new-joint-venture-agreement-with-Nano.pdf

Chordate's initial analysis indicates that this is a so-called DeNovo application, and the company has focused the project on tentatively moving forward to the submission of a complete application during the second half of 2022.

"As a natural step after the CE mark came into place in May earlier this year, we now want to move forward with market permits in the US as well. This is a longer project, but an important step to take in the strategy of building company value. This ambition to procure a US market permit does not mean that we have changed the model on how we build our proof of market. However, our assessment is that an approved DeNovo application in the long run gives us a broader set of options and makes Chordate more interesting for the medtech industry in general", says Anders Weilandt, CEO of Chordate.

"The project is to first carry out a pre-study to select the appropriate strategy, then a pre-submission step to understand the perspective of the FDA on a tentative submission, and finally the formal application. An important issue is to find out what level of scientific evidence the FDA wants to see in an application for acceptance. This will take time and need a clear focus on our part."

Information:

This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on October 13th, 2021, at 10:00 a.m. CET.

Anders Weilandt
Managing Director
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-Medical-Holding-AB-Publ-launches-pre-study-for-FD.pdf

Chordate-Medical-Holding-AB-Publ-launches-pre-study-for-FD.pdf